Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03266393 · ClinicalTrials.gov registry record · Phase 4
Envarsus XR® in Adolescent Renal Transplant Recipients
A Phase 4 study of Kidney Transplantation and Renal Transplantation, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03266393 is a Phase 4 study of Kidney Transplantation and Renal Transplantation that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 28 participants, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03266393, a Phase 4 study of Kidney Transplantation and Renal Transplantation, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Adolescents commonly experience barriers to adherence that entail forgetfulness, distraction, poor planning, and scheduling problems. A once daily oral regimen may be superior to the current regimens that require twice daily dosing. It is currently unclear if Envarsus XR® would improve outcomes in adolescent organ transplant recipients. Each patient will receive tacrolimus (twice daily immediate release oral formulation) which they are using as part of their standard of care immunosuppressive regimen for a portion of the study and Envarsus XR® (a once daily extended-release oral tacrolimus formulation) for a portion of the study in a cross-over design. Besides the advantage to adherence behaviors, a sustained-release tacrolimus preparation may decrease burdensome side effects and increase quality of life. Following enrollment, each patient will be maintained in the study for 9 months.
Conditions Studied
Interventions
- DRUG Tacrolimus
- DRUG Envarsus XR
Study Locations (1)
California
- UCLA Transplantation Services - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03266393
The ClinicalTrials.gov registry entry for NCT03266393 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (90% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Tacrolimus is the first listed.
NCT03266393 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03266393 about?
NCT03266393 is a clinical study titled "Envarsus XR® in Adolescent Renal Transplant Recipients". Adolescents commonly experience barriers to adherence that entail forgetfulness, distraction, poor planning, and scheduling problems. A once daily oral regimen may be superior to the current regimens that require twice daily dosing. It is currently unclear if Envarsus XR® would improve outcomes in a...
What is the current status of trial NCT03266393?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2019-01-15. Estimated completion is 2023-03-31.
What conditions does trial NCT03266393 study?
This clinical trial studies the following conditions: Kidney Transplantation, Renal Transplantation, Grafting, Kidney.
What interventions are being tested in trial NCT03266393?
The interventions under investigation include: Tacrolimus (DRUG), Envarsus XR (DRUG).
Who is sponsoring clinical trial NCT03266393?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03266393 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
RECRUITING · Phase 4
-
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
COMPLETED · Phase 4
-
Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
COMPLETED · Phase 4
-
Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
COMPLETED · Phase 4
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Prehabilitation for Kidney Transplant Candidates
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.